Correlation Between Relief Therapeutics and Sino Biopharmaceutica

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Relief Therapeutics and Sino Biopharmaceutica at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Relief Therapeutics and Sino Biopharmaceutica into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Relief Therapeutics Holding and Sino Biopharmaceutical Ltd, you can compare the effects of market volatilities on Relief Therapeutics and Sino Biopharmaceutica and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Relief Therapeutics with a short position of Sino Biopharmaceutica. Check out your portfolio center. Please also check ongoing floating volatility patterns of Relief Therapeutics and Sino Biopharmaceutica.

Diversification Opportunities for Relief Therapeutics and Sino Biopharmaceutica

0.14
  Correlation Coefficient

Average diversification

The 3 months correlation between Relief and Sino is 0.14. Overlapping area represents the amount of risk that can be diversified away by holding Relief Therapeutics Holding and Sino Biopharmaceutical Ltd in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Sino Biopharmaceutical and Relief Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Relief Therapeutics Holding are associated (or correlated) with Sino Biopharmaceutica. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Sino Biopharmaceutical has no effect on the direction of Relief Therapeutics i.e., Relief Therapeutics and Sino Biopharmaceutica go up and down completely randomly.

Pair Corralation between Relief Therapeutics and Sino Biopharmaceutica

Assuming the 90 days horizon Relief Therapeutics Holding is expected to under-perform the Sino Biopharmaceutica. In addition to that, Relief Therapeutics is 2.02 times more volatile than Sino Biopharmaceutical Ltd. It trades about -0.11 of its total potential returns per unit of risk. Sino Biopharmaceutical Ltd is currently generating about -0.07 per unit of volatility. If you would invest  905.00  in Sino Biopharmaceutical Ltd on December 2, 2024 and sell it today you would lose (99.00) from holding Sino Biopharmaceutical Ltd or give up 10.94% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthInsignificant
Accuracy95.38%
ValuesDaily Returns

Relief Therapeutics Holding  vs.  Sino Biopharmaceutical Ltd

 Performance 
       Timeline  
Relief Therapeutics 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Relief Therapeutics Holding has generated negative risk-adjusted returns adding no value to investors with long positions. Despite inconsistent performance in the last few months, the Stock's basic indicators remain nearly stable which may send shares a bit higher in April 2025. The current disturbance may also be a sign of long-run up-swing for the company stockholders.
Sino Biopharmaceutical 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Sino Biopharmaceutical Ltd has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest uncertain performance, the Stock's primary indicators remain strong and the current disturbance on Wall Street may also be a sign of long term gains for the company investors.

Relief Therapeutics and Sino Biopharmaceutica Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Relief Therapeutics and Sino Biopharmaceutica

The main advantage of trading using opposite Relief Therapeutics and Sino Biopharmaceutica positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Relief Therapeutics position performs unexpectedly, Sino Biopharmaceutica can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Sino Biopharmaceutica will offset losses from the drop in Sino Biopharmaceutica's long position.
The idea behind Relief Therapeutics Holding and Sino Biopharmaceutical Ltd pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.

Other Complementary Tools

Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Stocks Directory
Find actively traded stocks across global markets
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance